tetano
Editor, Senior Moderator
Sci Adv
. 2025 Feb 7;11(6):eadp5539.
doi: 10.1126/sciadv.adp5539. Epub 2025 Feb 7. A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform
Yingying Jiang[SUP] 1 2 3 [/SUP], Mrinmoy Sanyal[SUP] 4 5 [/SUP], Noor A Hussein[SUP] 6 [/SUP], Ani Baghdasaryan[SUP] 1 [/SUP], Mengzhen Zhang[SUP] 1 [/SUP], Feifei Wang[SUP] 1 3 7 [/SUP], Fuqiang Ren[SUP] 1 [/SUP], Jiachen Li[SUP] 1 [/SUP], Guanzhou Zhu[SUP] 1 [/SUP], Yifan Meng[SUP] 1 [/SUP], Julia Zofia Adamska[SUP] 8 9 [/SUP], Elizabeth Mellins[SUP] 6 [/SUP], Hongjie Dai[SUP] 1 2 3 [/SUP]
Affiliations
The COVID-19 pandemic caused a global health crisis that resulted in millions of deaths. Effective vaccines have played central roles in curtailing the pandemic. Here, we developed a down-converting near-infrared IIb (NIR-IIb; 1500 to 1700 nanometers) luminescent, pure NaErF[SUB]4[/SUB]@NaYF[SUB]4[/SUB] rare-earth nanoparticle (pEr) as vaccine carriers. The pEr nanoparticles were coated with three layers of cross-linked biocompatible polymers (pEr-P[SUP]3[/SUP]; ~55 nanometers) and conjugated to the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Upon subcutaneous injection of the pEr-P[SUP]3[/SUP]-RBD nanovaccine in mice, in vivo NIR-IIb imaging revealed active vaccine trafficking and migration to lymph nodes through lymphatic vessels. Two doses of the adjuvant-free vaccine elicited long-lasting (>7 months) high titers of serum viral neutralization antibody and anti-RBD immunoglobulin G, along with robust RBD-specific germinal center B cells and T follicular helper cells. We devised in vivo NIR-II molecular imaging of RBD-specific cells in lymph nodes, opening noninvasive assessments of vaccine-elicited immune responses longitudinally.
. 2025 Feb 7;11(6):eadp5539.
doi: 10.1126/sciadv.adp5539. Epub 2025 Feb 7. A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform
Yingying Jiang[SUP] 1 2 3 [/SUP], Mrinmoy Sanyal[SUP] 4 5 [/SUP], Noor A Hussein[SUP] 6 [/SUP], Ani Baghdasaryan[SUP] 1 [/SUP], Mengzhen Zhang[SUP] 1 [/SUP], Feifei Wang[SUP] 1 3 7 [/SUP], Fuqiang Ren[SUP] 1 [/SUP], Jiachen Li[SUP] 1 [/SUP], Guanzhou Zhu[SUP] 1 [/SUP], Yifan Meng[SUP] 1 [/SUP], Julia Zofia Adamska[SUP] 8 9 [/SUP], Elizabeth Mellins[SUP] 6 [/SUP], Hongjie Dai[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 39919189
- PMCID: PMC11804919
- DOI: 10.1126/sciadv.adp5539
The COVID-19 pandemic caused a global health crisis that resulted in millions of deaths. Effective vaccines have played central roles in curtailing the pandemic. Here, we developed a down-converting near-infrared IIb (NIR-IIb; 1500 to 1700 nanometers) luminescent, pure NaErF[SUB]4[/SUB]@NaYF[SUB]4[/SUB] rare-earth nanoparticle (pEr) as vaccine carriers. The pEr nanoparticles were coated with three layers of cross-linked biocompatible polymers (pEr-P[SUP]3[/SUP]; ~55 nanometers) and conjugated to the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Upon subcutaneous injection of the pEr-P[SUP]3[/SUP]-RBD nanovaccine in mice, in vivo NIR-IIb imaging revealed active vaccine trafficking and migration to lymph nodes through lymphatic vessels. Two doses of the adjuvant-free vaccine elicited long-lasting (>7 months) high titers of serum viral neutralization antibody and anti-RBD immunoglobulin G, along with robust RBD-specific germinal center B cells and T follicular helper cells. We devised in vivo NIR-II molecular imaging of RBD-specific cells in lymph nodes, opening noninvasive assessments of vaccine-elicited immune responses longitudinally.